Fuzeon (Enfuvirtide, T-20)
| Brand Name: |
Fuzeon |
| Generic Name: |
Enfuvirtide, T-20 |
| Adult Single Dose: |
Patients weighing more than 94 lbs
(42.6 kg): 90 mg (1 mL) injected subcutaneously into the upper arm,
thigh, or abdomen (twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
FI |
|
|
|
The Basics
- An Overview of Fuzeon (Enfuvirtide, T-20) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Enfuvirtide (Fuzeon) (May 24, 2009)
To read PDF, click here
From AIDS InfoNet
- Fuzeon (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Patient Information About Fuzeon (Enfuvirtide, T-20) (PDF) (December 2008)
From Roche
- Characteristics of Fusion and Integrase Inhibitors, and CCR5 Antagonists (PDF) (November 3, 2008)
An excerpt from the official U.S. HIV treatment guidelines for adults and adolescents. For the full guidelines, click here (PDF).
From AIDSinfo
- Fuzeon (Enfuvirtide, T-20) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Important Changes to Fuzeon Product Labeling (January 31, 2007)
From U.S. Food and Drug Administration
- Fuzeon (Enfuvirtide, T-20) Patient Product Information (PDF) (November 2006)
From Roche
- T-20 (Enfuvirtide, Fuzeon) (August 15, 2006)
From AIDS Treatment Data Network
- Transcript of The Body's Live Chat on Fuzeon (T-20, Enfuvirtide) (October 25, 2004)
From The Body
- Transcript of The Body's Live Chat on Fuzeon (T-20, Enfuvirtide) (June 16, 2004)
From The Body
- Fuzeon: The Basics (October 2003)
In Fuzeon -- A Review of the First Entry Inhibitor, from The Body
- Ten Tips on Injecting Fuzeon (October 2003)
In Fuzeon -- A Review of the First Entry Inhibitor, from The Body
- Fuzeon (Enfuvirtide, T-20) Injection Instructions (PDF) (March 2003)
From Roche
First Person
|
|
Advertisement
|
E-Mail
Glossary
Share
